In Brief
The mechanisms by which IL-10 facilitates the establishment of chronic infections are not fully understood. Smith et al. demonstrate that during chronic infections, IL-10 upregulates N-glycan branching on CD8 + T cell surface glycoproteins, which reduces signal transduction downstream of the T cell receptor and decreases CD8 + T cell antigen sensitivity and capacity to control pathogen burden.
INTRODUCTION
Chronic viral infections, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV), remain a tremendous global health burden threatening a significant proportion of the population. These infections lead to progressive immune dysfunction, including the functional exhaustion and eventual deletion of the responding T lymphocytes (Wherry and Kurachi, 2015) . While the consequences of chronic viral infections on the host immune system are well described, less is known of the early events that allow for the establishment of viral persistence. CD8 + T cells play a critical role in the immune response to viral infections and are central to the capacity of the host to prevent the establishment of chronic infection (Barber et al., 2006) . Efficient pathogen control relies on the capacity of CD8 + T cells to rapidly respond and develop effector functions in the presence of low levels of antigen, also known as antigen sensitivity or functional avidity (Alexander-Miller, 2005; Viganò et al., 2012; Walker et al., 2010) . The importance of antigen sensitivity is best illustrated by the findings that patients who can resolve multiple HCV infections harbor highly sensitive HCV-specific CD8 + T cells compared to patients who progress to chronic infection (Abdel-Hakeem et al., 2017) . Thus, antigen sensitivity of the responding CD8 + T cells may be a key characteristic that determines whether the immune response is able to rapidly and efficiently control the invading pathogen. The affinity of the T cell receptor (TCR) for peptide antigen is relatively low and, as opposed to the B cell receptor, remains fixed during the lifetime of the cell. However, the antigen sensitivity of CD8 + T cells is modulated during infection at both the population (Busch and Pamer, 1999; Malherbe et al., 2004; Zehn et al., 2009 ) and single cell (Richer et al., 2013; Slifka and Whitton, 2001) level. Individual CD8 + T cell clones become more sensitive to their cognate antigen when they encounter inflammatory cytokines such as type I interferons and interleukin (IL)-12 (Richer et al., 2013) . Exposure to inflammatory cytokines enhances the TCR signal transduction capacity of CD8 + T cells, thereby reducing the threshold of antigen necessary for the induction of effector functions such as the production of cytokines and cytolysis (Richer et al., 2013) . This represents an important regulatory loop that couples the presence of inflammatory cytokines to the activation of T cells, which likely limits immunopathology. However, because the antigen sensitivity of CD8 + T cells is modulated by extrinsic factors, these regulatory circuits could potentially favor persistence if they are inappropriately activated during infection. It is currently unknown whether the 
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antigen sensitivity of CD8 + T cells is modulated in the context of chronic viral infections or how this might be regulated.
Chronic viral infections induce an inflammatory milieu that is distinct from those established by acute viral infections (Ng and Oldstone, 2014b) . These differences include changes in both the duration of the inflammatory period and cytokines produced. Several chronic viral infections, including HIV and HCV, are associated with sustained induction of IL-10 in humans (Mannino et al., 2015) . IL-10 is a broad spectrum immunoregulatory cytokine that can inhibit the function of a variety of immune cells and plays a critical role in dampening inflammatory responses (Corinti et al., 2001; Moore et al., 2001) . Increased serum detection of IL-10 coincides with disease progression in patients with active HIV infection (Kwon and Kaufmann, 2010) . Additionally, elevated IL-10 signatures at early time points following HCV challenge is associated with chronic progression of the disease (Flynn et al., 2011) . Thus, the induction of IL-10 is a common feature of pathogens that can establish chronic infections.
The role of IL-10 during the establishment of viral persistence is clearly supported in mouse models of chronic viral infection. Infection of mice with lymphocytic choriomeningitis virus strain clone 13 (LCMV cl13) establishes chronic infection and induces heightened and sustained production of IL-10, compared to acute infection with the closely related LCMV Armstrong (Arm) strain. The induction of IL-10 plays an important role in the establishment of persistence by LCMV cl13 as genetic deficiency of IL-10-or antibody-mediated blockade of the IL-10 receptor alpha chain (IL-10Ra) results in enhanced viral control (Brooks et al., 2006; Ejrnaes et al., 2006) . The mechanisms linking the production of IL-10 to the establishment of chronic infection and the cellular targets of IL-10 in this model remain major knowledge gaps.
We have previously shown that pro-inflammatory cytokines impact the antigen sensitivity of CD8 + T cells (Richer et al., 2013 ). Thus, we tested the hypothesis that the anti-inflammatory cytokine IL-10 induced during chronic infection increases the threshold of antigen necessary for CD8 + T cell activation, thereby enabling the pathogen to outpace the immune response and establish persistence. We observed that IL-10 induced in the context of LCMV cl13 triggered an N-glycan branchingmediated immunoregulatory loop that was associated with decreased CD8 + T cell antigen sensitivity, thereby facilitating the establishment of chronic infection.
RESULTS
IL-10 Directly Reduces the Antigen Sensitivity of Antigen-Specific CD8 + T Cells We previously showed that cytokines regulate the antigen sensitivity of CD8 + T cells (Richer et al., 2013) . As chronic viral infections establish a distinct inflammatory milieu that is characterized by the induction of IL-10 (Brooks et al., 2006; Ejrnaes et al., 2006; Parish et al., 2014) , we asked whether a virus that establishes chronic infections negatively regulates the antigen sensitivity of CD8 + T cells to counter immune defenses. To address this question, we transferred congenically marked P14 TCR transgenic T cells into wild-type (WT) or IL-10-deficient hosts (Il10 À/À ). CD8 + T cells from this transgenic mouse line express a TCR specific to GP [33] [34] [35] [36] [37] [38] [39] [40] [41] (an immunodominant epitope of LCMV), allowing us to measure the influence of the inflammatory milieu on a population sharing identical TCRs and therefore identical affinity for their cognate antigen. Following adoptive transfer, mice were infected with either LCMV Armstrong (Arm) or LCMV clone 13 (cl13) to induce either acute or chronic infection, respectively, and antigen sensitivity was measured at day 8 post-infection (Richer et al., 2013) . Infection with LCMV cl13 impaired the antigen sensitivity of effector P14 cells compared to effector P14 cells from mice infected with LCMV Arm ( Figures 1A, 1B , S1A, and S1B). Compared to P14 cells from LCMV cl13-infected mice, the antigen sensitivity of P14 cells from LCMV Arm-infected mice was higher based on the peptide concentration required to induce 50% of the maximum interferon (IFN)-g or tumor necrosis factor (TNF)-a production (effective concentration 50 [EC 50 ]) (Figures 1B and S1B) . In the absence of IL-10, the antigen sensitivity of P14 cells from LCMV cl13-infected mice was completely restored ( Figures 1A, 1B , S1A, and S1B). Conversely, IL-10 deficiency had no effect on antigen sensitivity of effector P14 cells during LCMV Arm infection ( Figures 1C and 1D ). In addition, absence of IL-10 during LCMV cl13 infection resulted in an increase in the number of P14 cells recovered as well as the percentage of these cells producing IFN-g and TNF-a ( Figures  S1C-S1E ). Further, we observed that P14 cells harvested from LCMV cl13-infected mice had a reduced capacity to kill target cells coated with low concentrations of peptide and this was restored in the absence of IL-10 ( Figure S1F ). The antigen sensitivity of P14 cells was also rescued via anti-IL-10R antibody blockade during LCMV cl13 infection in WT mice (Figures S1G and S1H) . Thus, infection with LCMV cl13 reduced the antigen sensitivity of CD8 + T cells in an IL-10-dependent manner.
During established chronic infections, persistent TCR stimulation leads to T cell exhaustion, a hypo-functional state where T cells fail to respond to antigen and express a high level of inhibitory receptors (Yi et al., 2010) . At day 8 post-infection, P14 cells from LCMV cl13-infected mice maintained heightened surface expression of the co-inhibitory receptors PD-1, Lag-3, CTLA-4, and Tim-3 irrespective of the presence of IL-10 ( Figures 1E,  1F , and S1I-S1N). Thus, the antigen sensitivity of CD8 + T cells can be restored in the absence of IL-10 independently of changes in the expression of inhibitory receptors, further suggesting that IL-10 and inhibitory receptors can induce T cell dysfunction through distinct mechanisms (Brooks et al., 2008 Figures 1G and 1H ), supporting that IL-10 can regulate antigen sensitivity in a CD8 + T cell-intrinsic manner.
IL-10 Impairs the TCR Signal Transduction Capacity of CD8 + T Cells We have previously shown that inflammatory cytokines can impact antigen sensitivity by increasing the efficiency of signal transduction downstream of the TCR (Richer et al., 2013) . Therefore, we asked whether IL-10 antagonizes TCR signal transduction leading to the increased antigen threshold required for activation. TCR ligation induces rapid phosphorylation of the kinase Zap-70 and activation of PLCg, leading to the eventual phosphorylation of AKT and ERK1/2, distal kinases activated downstream of the signaling cascade (Smith-Garvin et al., 2009) . To measure these signaling events at day 8 post-infection, we stimulated enriched P14 cells by CD3ε-crosslinking to induce activation in the absence of antigen presenting cells (APCs). P14 cells isolated from LCMV cl13-infected mice demonstrated a defect in the activation of these signaling pathways despite no changes in overall protein expression ( Figure 1I ). P14 cells isolated from IL-10-deficient mice infected with LCMV cl13 exhibited restored TCR signaling capacity ( Figure 1I ). Further, P14 cells from LCMV cl13-infected mice showed no defect in ERK1/2 activation following stimulation with phorbol myristate acetate (PMA; Figure 1J ), which bypasses the proximal signaling machinery. These data showed that P14 cells from LCMV cl13-infected mice maintain the capacity for robust MAP kinase activation when the TCR proximal signaling machinery is bypassed. This defect in signal transduction is not associated with a change in the expression of surface components of the TCR or costimulatory molecules, as we observed that infection with LCMV cl13 did not alter the surface expression of the alpha (Va2) and beta (Vb8.1) chains of the TCR, CD3ε, co-receptor CD8 or the costimulatory molecule CD28 ( Figure S2) . Together, these data demonstrated that infection with LCMV cl13 induces an IL-10-dependent TCR-proximal signaling defect that is associated with decreased antigen sensitivity.
IL-10 Impairs TCR:CD8 Co-localization during LCMV cl13 Infection T cell activation requires the clustering of several membrane proteins to induce effective and robust signal transduction. The TCR and co-receptor CD8 exist in distinct lipid microdomains within the T cell plasma membrane (Demotte et al., 2008) . Upon interacting with antigen, large-scale re-organization of the plasma membrane allow for both TCR and CD8 to interact with peptide:MHC class I on the APCs leading to signal transduction. The interaction between TCR and the CD8 co-receptor increases the affinity for peptide:MHC complex leading to increased antigen sensitivity even when T cells are stimulated in absence of APCs through CD3 cross-linking (Borger et al., 2014; Cawthon and Alexander-Miller, 2002) .
Because the capacity of the TCR to interact with the CD8 coreceptor and to form micro-clusters is integral to dictating antigen sensitivity, we hypothesized that reduced TCR and CD8 co-receptor association is linked to a decrease in CD8 + T cell antigen sensitivity. To test whether TCR:CD8 co-localization is impaired during LCMV cl13 infection, we used a well-defined flow cytometry adapted Fӧrster resonance energy transfer (FRET) approach ( Figure 2A ; Demotte et al., 2008) . On day 8 post-infection with LCMV Arm, we observed robust co-localization of TCR and CD8 on P14 cells and this was reduced on P14 cells isolated from LCMV clone 13-infected mice (Figures 2B and S3A) . TCR and CD8 co-localization was rescued in P14 cells isolated from LCMV cl13-infected Il10 À/À mice (Figures 2B and S3A), correlating with their restored TCR signaling capacity and antigen sensitivity ( Figure 1 ). These data suggested that infection with LCMV cl13 can lead to IL-10-induced impairment of the capacity of CD8 + T cells to co-localize the TCR and CD8 co-receptors and this is correlated with reduced T cell responsiveness to antigen.
LCMV cl13 Infection Increases N-glycan Branching on T Cells in an IL-10-Dependent Manner
The expression of Mgat5, a Golgi-resident glycosyltransferase, has been shown to restrict TCR clustering by increasing the branching of N-glycans on the surface of T cells at steady state (Demetriou et al., 2001 ). Mgat5-modified N-glycans can be further extended resulting in high-affinity binding sites for the galectin family of soluble b-galactoside binding lectins ( Figure 2C ; Ilarregui et al., 2005) . Galectin binding of surface glycoproteins forms a lattice that restricts protein diffusion due to multivalent interactions with multiple glycoproteins (Elola et al., 2015; Ilarregui et al., 2005) . However, whether this is a mechanism governing CD8 + T cell activation and whether this can be modulated infection and this increase was dependent on IL-10 ( Figures 2E  and 2F ). Mgat5-mediated glycosylation facilitates binding of galectin 3 (Gal3) to the TCR, thereby limiting its redistribution (Demetriou et al., 2001 ). Thus, we asked whether Mgat5-modified glycans were detectable on the TCR specifically. At day 8 after infection, we precipitated Mgat5-modified glycoproteins from whole P14 cell lysates using PHA-L-conjugated agarose beads. PHA-L beads precipitated detectable TCR only from T cells from WT mice infected with LCMV cl13 and not from LCMV Arm-infected WT mice or LCMV cl13-infected Il10 À/À mice ( Figure 2G ).
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Thus, Mgat5-mediated glycosylation of the TCR was enhanced during LCMV cl13 infection in an IL-10-dependent manner.
Chronic Plasmodium and HCV Infections Regulate Expression of Mgat5
To address whether other pathogens that establish chronic infection can also regulate the expression of Mgat5 in CD8 + T cells during the early stages of infection, we used a murine model of chronic parasitic infection. We adoptively transferred congenically marked P14 cells and subsequently infected mice with Plasmodium yoelii (a parasite that induces sustained IL-10 production and stimulates T cell exhaustion) (Butler et al., 2011; Kobayashi et al., 1996) expressing the model antigen GP 33-41 of LCMV. At day 7 after infection, we observed increased expression of Mgat5 and Il10ra compared to naive P14 cells ( Figures 2H and S3C ). Thus, these data suggested that the induction of Mgat5 may represent a conserved mechanism that limits T cell responses and favors the establishment of persistent or prolonged infections. We next asked whether this mechanism of regulation is also observed during chronic viral infections in humans. To address this, we examined the expression of MGAT5 and IL10RA in CD8 + T cells isolated from peripheral blood of subject with chronic infection HCV (a chronic viral infection that has also been associated with the induction of IL-10 [Frebel et al., 2010] ). We observed that CD8 + T cells from subjects chronically infected with HCV expressed higher levels of MGAT5 and IL10RA compared to CD8 + T cells from HCV naive individuals from the same cohort ( Figures 2I and S3D) . Therefore, our data showed that chronic infections in humans also result in increased MGAT5 expression by CD8 + T cells.
Galectin Inhibition Restores CD8 + T Cell Antigen Sensitivity While we observed an increase in Mgat5 expression and N-glycan branching, this would not be sufficient to restrict surface receptor interaction unless the N-glycans are engaged to form a restrictive network. The galectin protein family has several diverse members that are ubiquitously expressed in both the intracellular and extracellular environment. Previous studies demonstrate that in T cells, Gal3 is the predominant galectin involved in restricting TCR clustering (Demetriou et al., 2001 S4E ) and rescued the TCR signaling capacity of CD8 + T cells ( Figure 3D ).
These data demonstrated that inhibiting galectin binding can rescue IL-10-mediated CD8 + T cell suppression. Treatment with D-Lactose had no effect on P14 cells isolated from LCMV Arm-infected mice ( Figures 3E and 3F ). Together, these data supported a model in which the inhibitory effects of IL-10 on antigen sensitivity and signal transduction are mediated by the binding of galectins on the surface of T cells.
Gal3 Deficiency Restores Antigen Sensitivity and Viral
Control Despite Increased N-glycan Branching Our data showed that broad galectin inhibition with the competitive inhibitor D-Lactose rescued antigen sensitivity and TCR signaling capacity (Figure 3 ). Because Gal3 is believed to be the dominant lectin involved in restricting TCR diffusion, we asked whether Gal3 plays a role in IL-10-mediated CD8 + T cell dysfunction during LCMV cl13 infection. To address this, we adoptively transferred congenically marked WT P14 cells into Gal3-deficient mice (Lgals3
) and subsequently infected them with LCMV cl13. At day 8 after infection, we observed that the absence of Gal3 restored the antigen sensitivity of P14 cells with an EC 50 comparable to that of P14 cells from LCMV Arm-infected WT mice ( Figures 4A and 4B ). The absence of Gal3 did not impact PD-1 expression, which remained high during LCMV cl13 infection, further suggesting that the effects of IL-10 on T cell function are independent of PD-1 expression ( Figures S5A and S5B ). In addition, reduced Gal3 binding on the surface of CD8 + T cells restored TCR:CD8 co-localization ( Figures 4C and S5C-S5E ) despite elevated PHA-L binding that was equivalent on P14 cells recovered from both WT and Lgals3 À/À mice infected with LCMV cl13 (Figures 4D and 4E ).
This suggested that, even in the absence of Gal3, LCMV cl13 infection induced an increase in Mgat5-modified N-glycan branching (as indicated by elevated PHA-L binding), but that binding of host-derived Gal3 was necessary to restrict T cell function. Together, these data suggested that Gal3 binding to glycoproteins on the surface of T cells plays a central role in mediating the IL-10-induced reduction in CD8 + T cell antigen sensitivity. The Lgals3 À/À mouse model allowed us to determine whether restoring CD8 + T cell antigen sensitivity leads to an improvement in the capacity of the host to control viral infection. Genetic deletion of Gal3 dramatically improved viral control with some mice clearing LCMV cl13 infection by day 8 and others exhibiting approximately 2 log reductions in viral titers in both the kidneys and the liver ( Figures 4F and  4G ). Enhanced virus control in Lgals3 À/À mice was not simply due to an increase in CD8 + T cell numbers, as T cell expansion was reduced relative to P14 cells responding to LCMV Arm infection ( Figure S5F ). Thus, despite increased N-glycan branching on T cells responding to LCMV cl13 in the presence of IL-10, Gal3 deficiency was associated with restored CD8 + T cell antigen sensitivity and increased capacity of the host to control viral infection.
Our previous experiments suggested a central role for IL-10 in increasing N-glycan on CD8 + T cells, thereby facilitating Gal3-mediated repression of T cell function and host protection. To investigate whether Mgat5 mediates these effects, we transduced P14 cells with retroviral constructs expressing shRNAs targeting Mgat5 or the irrelevant gene Firefly luciferase (shMgat5 and shFF luc , respectively). At day 8 post-infection with LCMV cl13, Mgat5 knockdown in P14 cells restored antigen sensitivity independently of any changes in the surface expression of PD-1 (Figures 5A-5D ). Mgat5 knockdown also decreased Gal3 binding and PHA-L staining on CD8 + T cells, showing that the reduction of Mgat5 expression decreased N-glycan branching ( Figures 5E-5H) . Conversely, transduced P14 cells expressing the control shRNA showed similar EC 50 s and similar binding of PHA-L and Gal3 compared to mock transduced cells (Figure 5) . Collectively, these data supported that the IL-10-mediated increase in Mgat5 expression is important to modify the glycosylation pattern on CD8 + T cells and is associated with T cell dysfunction during LCMV cl13 infection. Arm infection (Brooks et al., 2006; Frebel et al., 2010 ). Thus, we tested whether dose and timing of exposure to IL-10 are important for the regulating of Mgat5 expression and N-glycan branching. We observed that expression of Mgat5 and increased N-glycan branching were dependent on the dose of IL-10 (Figures 6A-6C) . Similarly, while short-term treatment with IL-10 (day 1 or day 1 and 2 of culture only) resulted in modestly increased expression of Mgat5 and N-glycan branching, sustained exposure to IL-10 (all days of culture) resulted in much greater expression of both ( Figures 6D-6F) . Thus, both the dose and the duration of exposure to IL-10 were critical for the regulation of N-glycan branching, which likely explains why this immunoregulatory loop is strongly engaged during LCMV cl13 but not LCMV Arm infection.
IL-10 Regulates
To investigate whether IL-10 acts on CD8 + T cells through canonical STAT3-dependent signaling pathways, we employed a previously described STAT3 inhibitor (WP1066) (Iwamaru et al., 2007) . We observed upregulation of Mgat5 expression following activation in the presence of IL-10, which was impaired by STAT3 inhibition ( Figure 6G ). Furthermore, upregulation of Mgat5 was associated with increased binding of PHA-L that was lost upon inhibition of STAT3 ( Figures 6H and S6A ). Because Gal3 was ubiquitously expressed and its expression was unchanged during LCMV infection ( Figures S3E and S3F ), substrate (branched N-glycans) availability likely acts as the ratelimiting step to galectin binding. Thus, we asked whether recombinant Gal3 supplied exogenously could recapitulate our in vivo observations. Indeed, exogenous recombinant Gal3 only bound to cells treated with IL-10 in the absence of STAT3 inhibitor (Figures 6I and S6B ), supporting our model that Mgat5-mediated glycan modifications is induced by IL-10 and acts as the limiting step to galectin-mediated repression. Treatment with other cytokines that signal through STAT3 such as IL-6 and IL-21 was not sufficient to induce Mgat5 expression ( Figure S6C ). Together, these data supported that IL-10 acted directly on CD8 + T cells in a STAT3-dependent manner to induce Mgat5 expression, which sensitized T cells to Gal3 binding. Our ex vivo experiments suggested a regulatory pathway through which IL-10 can inhibit CD8 + T cells by inducing leading to increased Gal3 binding and reduced antigen sensitivity contributing to T cell dysfunction during the establishment of chronic viral infection.
DISCUSSION
While the impact of chronic infections on host immune function, particularly the progressive development of T cell exhaustion, has been well described (Wherry and Kurachi, 2015) , the early events allowing pathogens to establish persistence remain less defined. Herein, we demonstrated that pathogens that establish chronic infections triggered reductions in CD8 + T cell antigen sensitivity and that this required CD8 + T cell-intrinsic IL-10 signaling. Mechanistically, our data supported a model in which IL-10 signaling, via STAT3, increased the expression of the glycosyltransferase Mgat5 leading to enhanced branched N-glycans on glycoproteins (including the TCR) on the surface of CD8 + T cells. Mgat5-modified N-glycans, in turn, served as ligands for the binding of Gal3 and the formation of a restrictive lattice that limited the capacity of TCR and the CD8 co-receptor to interact, which was associated with a defect in TCR signal transduction. This reduction in CD8 + T cell antigen sensitivity increased the antigenic threshold required for T cell activation, which may allow the rapidly replicating pathogen to outpace the immune system and establish persistence. Together, our data suggested a mechanism of CD8 + T cell regulation by antiinflammatory cytokines that act through post-translational modification networks to modulate TCR sensitivity and CD8 + T cell function. In addition, our data revealed that this regulatory loop is inappropriately activated during certain infections and is associated with the establishment of persistence. IL-10 is an important immunomodulatory cytokine that impacts a variety of cell types. While the inhibitory role of IL-10 on APCs and CD4 + T cells is becoming well defined, much less was known about its impact on CD8 + T cells (Ip et al., 2017; Krawczyk et al., 2010) . In fact, previous research shows that IL-10 can have a stimulatory role for CD8 + T cells, aiding in tumor regression and acting as a substitute for signal 3 in the absence of IL-2 (Emmerich et al., 2012; Santin et al., 2000) . Conversely, our data supported that IL-10 can act directly on CD8 + T cell to exert specific inhibitory effects. Similar paradoxical effects of cytokines, such as type I interferon, have been documented during chronic viral infections (Ng and Oldstone, 2014a; Wilson and Brooks, 2011) . Thus, the specific timing and inflammatory context likely play an important role in the transcriptional network and effects induced by IL-10 on CD8 + T cells. In fact, our data supported that both the dose and duration of exposure to IL-10 are critical to engage this regulatory loop, likely explaining why it is engaged only during the establishment of chronic infection.
N-glycosylation of the TCR is an established regulator of T cell antigen sensitivity, as mutational approaches reducing N-glycosylation can improve the sensitivity of T cells for their antigen (Kuball et al., 2009 ). Mgat5 plays a central role in regulating the activation of T cells by modulating the branching of N-glycans. Previous studies demonstrate that Mgat5-deficient naive T cells spontaneously cluster their TCR and have a lower antigenic threshold for activation at steady-state (Demetriou et al., 2001 ). In addition, Mgat5-deficient mice develop spontaneous autoimmunity and are more susceptible to the induction of experimental encephalomyelitis (EAE), clearly highlighting the importance of this enzyme as a gatekeeper of T cell activation (Demetriou et al., 2001; Grigorian and Demetriou, 2011) . Here, we demonstrated that IL-10 signaling directly to CD8 + T cells enhanced the expression of Mgat5 to negatively regulate CD8 + T cell function. This novel regulatory loop appears conserved across several infections and in humans, as we observed that CD8 + T cells from mice infected with Plasmodium yoelii (a parasite that establishes chronic infection) and from patients chronically infected with HCV express elevated levels of Mgat5 transcripts. Our data established modulation of N-glycan branching as a critical rate-limiting step of the Gal3-mediated suppression of T cell function. This is supported by the observation that Gal3 expression is not regulated during LCMV infection and by the inability of CD8 + T cells to bind exogenously provided Gal3 unless they were stimulated in the presence of IL-10. One remaining question is how IL-10 regulates the expression of Mgat5. While our data supported that the increased expression of Mgat5 depends on the canonical STAT3 signaling pathway, there are no STAT3 consensus binding sites within the Mgat5 promoter region. One possibility is that STAT3 may complex with ETS-1 to potentiate Mgat5 transcription as STAT3-ETS-1-SP1 transcriptional complexes have been described, and ETS-1 is a documented regulator of Mgat5 (Bian et al., 2011; Kang et al., 1996) . Alternatively, STAT3 signaling may lead to the induction of other transcription factors leading to enhanced Mgat5 expression. In support of this, STAT3 is known to direct the expression and epigenetic modifications of a number of transcription factors in T cells (Durant et al., 2010) . Determining how IL-10 regulates Mgat5 expression will be the subject of future investigations. The regulation of Mgat5 by IL-10 over the course of infection may represent an immunoregulatory loop that plays an important role even during a protective immune response. This may serve to prevent some CD8 + T cells from becoming terminally differentiated, thereby maintaining their capacity to develop into memory CD8 + T cells. In support of this, IL-10 plays an important role in the development of memory CD8 + T cells following clearance of infection (Cui et al., 2011) . While some of the role of IL-10 in that context is to insulate the T cells from the effects of other inflammatory cytokines, it is tempting to speculate that it may also have a direct effect on CD8 + T cells by regulating Mgat5 expression and N-glycan branching. In the context of chronic infections, the sustained and heightened production of IL-10 may simply amplify this regulatory loop, leading to the inability of T cells to respond efficiently, thereby favoring the establishment of pathogen persistence. Our data suggested that the galectin N-glycan lattice dampens CD8 + T cell antigen sensitivity during chronic viral infections and that this step is controlled by IL-10 signaling to CD8 + T cells. We showed that disruption of this regulatory pathway restored some T cell function during infection and is associated with better viral control. Of note, tumor-derived IL-10 plays an important role in immune evasion in some cancers and local administration of galectin inhibitors can restore immune detection and reduce tumor burden in these models (Demotte et al., 2010; Sun et al., 2015) . Therefore, pharmacological inhibition of IL-10 or Mgat5 regulatory circuits may also provide a more targeted approach to reinvigorating anti-tumor or anti-viral immunity. As our data supported that these regulatory pathways may be distinct from the exhaustion pathways mediated by checkpoint blockade inhibitors, this suggests that these new therapies could be used in conjunction with checkpoint blockade to ameliorate patient outcomes.
In conclusion, our data provided mechanistic insight into the impact of IL-10 on CD8 + T cells. We propose a model in which IL-10 induced by infection with LCMV cl13 directly regulates the expression of Mgat5, leading to heightened Mgat5-modified N-glycan branching on CD8 + T cells that enhances binding of Gal3. Elevated Gal3 binding restricts TCR:CD8 co-receptor association and reduces TCR signaling capacity ultimately decreasing CD8 + T cell antigen sensitivity. Thus, our data suggest a regulatory pathway that leads to dysfunction of T cells during persistent infections and identifies pathways that may provide novel therapeutic targets to potentially enhance the T cell response to chronic viral infections and cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to the Lead Contact, Martin J. Richer (martin.j.richer@mcgill.ca) EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice C57BL/6 and Il10 À/À mice were originally purchased from Charles River Laboratories and The Jackson Laboratory, respectively and bred in house. Mice with P14 TCR-tg CD8 + T cells were previously described (Pircher et al., 1987) and were provided by Dr. A. Lamarre (INRS-Institut Armand-Frappier) and bred in house. Lgals3 À/À mice were provided by Dr. D. Sheppard (McGill University). Infected mice where housed in biocontainment level 2 and all animal procedures were carried out in accordance with the Canadian Council on Animal Care and were approved by the McGill University Animal Care Committee. 6-12 week old mice of both sexes were used for all experiments Pathogens LCMV Armstrong and LCMV clone 13 were kindly provided by Dr. J. Harty (University of Iowa) and Dr. T. Watts (University of Toronto) from a strain originally propagated by Dr. M. Oldstone (The Scripps Research Institute), respectively. LCMV was propagated as described (Slifka and Whitton, 2001 ). Mice were infected with 2 3 10 5 plaque forming units (PFU) of LCMV Armstrong by intraperitoneal (i.p.) injection, or 2 3 10 6 PFU LCMV clone 13 intravenous (i.v.) injection, respectively (Richer et al., 2013; Wherry et al., 2003) . Viral titers were determined by plaque assay conducted on Vero cells (Ahmed et al., 1984) . Briefly, Vero cell monolayers were infected with 100 mL of serially diluted kidney or liver sample and incubated for 90 minutes at 37 C in 5% CO 2 . Agarose overlay was added to infected cells and placed in incubator for 3 days at 37 C in 5% CO 2 . Cells were then stained with agarose overlay supplemented with 1% neutral red for 2 days at 37 C in 5% CO 2 and plaques were counted. 
Cell lines
All cells were cultured at 37 C with 5% CO 2. Green monkey VERO cells (female origin, provided by Dr. S. Varga, University of Iowa) and Human embryonic kidney tubule HEK293T cells (female origin) were cultured in Dulbecco's Modified Eagle Medium supplemented with 1% non-essential amino acids, 1% penicillin and streptomycin, 2mM L-glutamine, 1% sodium pyruvate and 10% heat-inactivated FBS. EL4 (female origin, provided by Dr. J. Harty, University of Iowa) suspension cells were cultured in RPMI 1640 supplemented with 1% penicillin and streptomycin, 2 nM L-glutamine, 25 mM HEPES, 50 mM b-mercaptoethanol and 10% heat-inactivated FBS.
Primary cells
All cells were cultured at 37 C with 5% CO 2 . For routine ex vivo peptide stimulation total splenocytes were cultured in RPMI 1640 supplemented with 1% penicillin and streptomycin, 2 nM L-glutamine, 25 mM HEPES, 50 mM b-mercaptoethanol and 10% heat-inactivated FBS. For ex vivo activation, expansion and transduction of P14 TCR-tg and wild-type CD8 + T cells, cells were cultured in Iscove's Modified Dulbecco's Medium supplemented with 1% penicillin and streptomycin, 2 nM L-glutamine, 25 mM HEPES, 50 mM b-mercaptoethanol and 10% heat-inactivated FBS.
METHOD DETAILS
Adoptive Transfer 2 -100 3 10 3 naive P14 TCR-tg CD8 + T cells were transferred by i.v. injection into congenically mismatched recipients at the Thy1 locus. 1 day following transfer mice were infected with the appropriate strain of LCMV. At day 8 post-infection mice were sacrificed and splenic CD8 + T cells were analyzed.
Ex vivo cytokine production 1 -3 3 10 6 splenocytes were incubated ex vivo with titrated concentrations of GP 33-41 peptide in the presence of BFA. Cells were stimulated for 6 hours at 37 C, 5% CO 2 and then stained for the production of cytokines by intracellular cytokine staining.
TCR signaling and Immunoblot 1 -10 3 10 4 naive P14 TCR-tg CD8 + T cells were injected i.v. into naive congenically mismatched recipients; 1 day later mice were infected with LCMV Arm or LCMV cl13, as indicated. On day 8 post-infection, spleens were harvested and transgenic cells were isolated by Thy1.1 or Thy1.2-PE positive-selection, accordingly. In brief, cells were stained with the appropriate PE conjugated antibody and purified using anti-PE-magnetic separation according to standard AutoMACS protocols (Miltenyi Biotec). 1 3 10 7 cells were stimulated by CD3ε crosslinking or PMA stimulation at 37 C; following stimulation cells were lysed with 25 -50 mL of NP-40 lysis buffer, accordingly. 15 -25 mg of protein was resolved by SDS-PAGE, transferred to PVDF membranes and probed with the indicated antibodies. Antibody binding was detected using goat-anti-rabbit conjugated to horseradish peroxidase and Amersham Prime ECL.
FRET TCR-CD8 FRET was measured using flow cytometry. 1 -5 3 10 6 total splenocytes were incubated for 30 minutes with PE-conjugated anti-Va2 (a component of the transgenic TCR) as a fluorescence donor and APC-conjugated anti-CD8a as a fluorescence acceptor. Samples were stained with either antibody (E PE , or E APC ), both (E Both ) or neither (E none ). Cells were concurrently labeled with CD3ε-biotin and stimulated by crosslinking with streptavidin for 2 minutes. Stimulated samples were subsequently fixed with IC Fixation buffer for 10 minutes and quantified by flow cytometry. FRET emission was assessed by flow cytometry without compensation, observing emission in the APC wavelength without direct laser excitation. FRET efficiency was calculated in FRET units (Perica et al., 2012 
Lactose treatment
For experiments measuring antigen sensitivity: 1 -3 3 10 6 splenocytes were incubated with titrated concentrations of peptide in the presence of BFA as described above. Prior to the 6 hour incubation cells were supplemented with 50 mM D-Lactose. For signaling experiments and FRET analysis: purified or total cells were supplemented with 50 mM D-Lactose and incubated for 30 min in 37 C water bath to disrupt galectin binding (Demetriou et al., 2001) . Cells were then processed as described above.
In vivo treatments
For experiments using anti-CD210 blocking antibody: mice received 50,000 congenically marked P14 TCR-tg CD8 + T cells by adoptive transfer, the following day mice were infected with LCMV cl13, as described above. At days 1 and 5 post-infection mice were treated with 500 mg of rat-anti-CD210 or rat-IgG1 isotype control by i.p. injection. Mice were sacrificed and analyzed at day 8 post-infection.
Branched N-glycan surface expression analysis Cells were treated with 50 mM D-Lactose to remove bound galectins, which may impair staining through steric hindrance. Cells were stained with fluorescently labeled antibodies for 20 minutes, then washed and fixed. Cells were incubated with 50 mg/mL biotinylated Phaseolus vulgaris Leukoagglutinin (PHA-L) for 1+ hour at room temperature, washed and incubated with PE-conjugated streptavidin and analyzed by flow cytometry.
PHA-L pull-down P14 cells were enriched from total splenocytes by standard AutoMACS protocol as described above. Isolated cells were treated with 50 mM D-Lactose for 30 minutes at 37 C, to remove any surface bound galectins and expose branched N-glycans. Cells were then pelleted by centrifugation, lysed in NP-40 lysis buffer, and quantified using a Bradford assay. 10% of whole cell lysate was reserved and loaded as the input fraction. 250 mg of total protein was incubated with 150 mg of PHA-L conjugated agarose beads at room temperature, overnight, with agitation. Beads were pelleted by centrifugation and washed 4 times with an equal volume of lysis buffer. Proteins were eluted using Laemmli sample buffer (Sigma Aldrich), and detected by SDS-PAGE followed by immunoblotting with anti-TCRa/b.
Cytolysis Assay EL4 cells were labeled with efluor 450 proliferation dye at either 100 nM or 0.05 nM (e450 hi and e450 lo , respectively). e450 lo cells were then incubated for 1 hour at 37 C with 5% CO 2 in the presence of 0.05 nM GP 33-41 peptide. Following incubation, both cell populations were washed and counted. e450 hi cells were mixed at a 1:1 ratio with e450 lo -target cells. 1 3 10 6 total EL4s were then seeded into a 96 well plate in 100 mL of medium. P14 TCR-tg CD8 + T cells were enriched from the spleen of day 8 infected mice according to standard Automacs protocols. 1.25 3 10 5 enriched P14 cells/well were co-cultured with EL4s (a 1:4:4 ratio of effector CD8 + T cells: e450 lo GP 33-41 pulsed target cells: e450 hi non-target cells) and incubated at 37 C with 5% CO 2 for 2 hours. Following incubation, cells were fixed with IC fixation buffer and analyzed by flow cytometry. Specific lysis was determined by the proportion of e450 lo target cells to e450 hi non-targets, relative to EL4s cultured alone.
Specific Lysis = 100% -([(% e450 lo target cells co-cultured / % e450 hi non-target cells co-cultured) / (% e450 lo target cells alone / % e450 hi non-target cells alone)] x 100%)
Gene expression analysis For RT-qPCR analysis, P14 cells were isolated by PE-selection as described above. RNA was then extracted (Trizol reagent) and 1 mg of total RNA was used to generate cDNA with iScript reverse transcriptase (Bio-Rad). RT-PCR analysis was then conducted using SensiFAST SYBR (Bioline). Transcript expression was normalized to TATA binding protein as an internal control and depicted as a relative fold change using the DDCt method, compared to the mean of the control group (Livak and Schmittgen, 2001 ).
CD8 + T cell transduction
Naive P14 cells were isolated from spleens by negative CD8 selection (STEMCELL technologies 19853) . 2 3 10 6 cells per well were stimulated with plate bound CD3ε and CD28 in the presence of 20 units/mL of recombinant murine IL-2 (eBioscience). 18 hours later, activated cells were either transduced using retrovirus produced in HEK293Ts transfected with LMPd-based retroviral vectors provided by Dr. M. Pipkin (The Scripps Research Institute, Florida) and Dr. S. Crotty (La Jolla Institute for Allergy and Immunology) encoding the shRNA of interest Paddison et al., 2004) or mock-transduced. Cells were allowed to recover for 6 hours prior to adoptive transfer into recipient mice that were infected with LCMV 6 hours prior.
Ex vivo IL-10 treatment Naive CD8 + T cells were isolated from spleens by negative CD8 selection (STEMCELL Technologies). 2 3 10 6 cells/mL were activated with plate bound CD3ε/CD28 in the presence of 20 units/mL of IL-2. Cells were treated with or without various doses of recombinant murine IL-10 (eBioscience) and with or without 0.5 nmol/mL the STAT3 inhibitor WP1066 (Sigma 573097). After 2 days, cells were transferred to plates without CD3ε/CD28 and maintained up to day 8 with or without addition of recombinant murine IL-10 as indicated at 37 C with 5% CO 2 .
MGAT5 expression from patient samples Study subjects were enrolled among people who inject drugs (PWIDs) participating in the Montreal Acute Hepatitis C Cohort Study (HEPCO) (Grebely et al., 2013) . This study was approved by the Institutional Ethics Committee of CRCHUM (Protocol SL05.014). All samples were anonymized. Chronic HCV infection was identified in participants who tested positive for HCV RNA for more than 6 months post initial infection as previously described (Badr et al., 2008; Grebely et al., 2013) . CD8 + T cells were isolated from cryopreserved peripheral blood mononuclear cells (PBMCS) from five chronically infected or HCV naive participants by MACS separation (Miltenyi Biotech). RNA was isolated using RNeasy Plus kit (QIAGEN). cDNA synthesis and RT-qPCR were performed as described above.
ELISA Galectin 3 abundance in the serum was determined by sandwich ELISA. Serum samples were diluted 1:4, 1:8 and 1:16 in assay diluent and incubated overnight at 4 C. Secondary anti-galectin-biotin was added for 1 hour at room temperature, streptavidin-HRP was added for 45 minutes at room temperature. Samples were developed using TMB substrate and read by measuring absorbance at 450 nm and 550 nm. Galectin 3 was quantified by comparison relative to serially diluted galectin 3 protein standard.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed with GraphPad Prism software. The Specific tests used to determine statistical significance are indicated in each figure legend. P values of less than 0.05 were considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
Data were analyzed using Flowjo and GraphPad Prism analysis software. Both packages are publically available through commercial vendors.
